Medifast AI Stock Analysis
Medifast (0K05) AI Stock Analysis
Medifast
(LSE:0K05)
No summary available
Medifast (0K05) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $136.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 207
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- 0.54
- Revenue Growth
- -30.28%
- EPS Growth
- -16409.29%
- Country
- UK
- Employees
- 380
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Personal Products & Services
Medifast Business Overview & Revenue Model
Company Description
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the...
Medifast Earnings Call Summary
The call was cautiously positive. Management highlighted successful execution of the Trilogy 3.0 launch, improving coach productivity, strong product adoption, a debt-free balance sheet, cost realignment, and a stated path to fourth-quarter profitability. However, these positives were offset by a 19.4% revenue decline, a substantial reduction in active earning coaches, continued GLP-1-related pressure on the traditional weight loss category, and significantly larger GAAP operating and net losses. The outlook is constructive but remains dependent on improving coach growth while sustaining productivity gains.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Medifast expects fourth quarter revenue to range from $55 million to $75 million and income per share for the quarter to range from $0.00 to $0.25; while it expects to continue to see the active earning coach count to decline through the end of the year, it expects to see continued coach productivity growth during the quarter, up both year over year and sequentially. For the full year 2026, it expects revenue to range from $280 million to $300 million and loss per share between $1.80 and $2.05, and on a non GAAP basis, loss per share between $0.45 and $0.70. It expects fourth quarter adjusted EBITDA, excluding interest income, to range from $2 million to $6 million, and for the full year 2026, adjusted EBITDA, excluding interest income, to range from $10 million to $14 million; the company is targeting profitability in the fourth quarter of 2026.
Medifast Risk Analysis
Medifast disclosed 25 risk factors in its most recent earnings report. Medifast reported the most risks in the "Ability to Sell" category.
Latest Risks Added
0 New RisksMedifast Peers Comparison
Overall Rating
WW54Neutral
MRM44Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0K05 | Medifast | 12.16 | 1.44 | 13.41% | |
| MRM | Medirom Healthcare Technologies, Inc. | 0.26 | -1.75 | -86.87% | |
| WW | WW International, Inc. | 8.63 | -12.50 | -59.16% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
